Shares of biotech company CureVac N.V. (CVAC) were in the spotlight on Thursday after the company’s fourth-quarter revenue fell below Wall Street estimates. The company reported a revenue of €14.5 ...

The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound ...

CureVac has just had a harsh reminder of the perilous nature of drug development, after reporting that its mRNA-based COVID-19 vaccine was just 47% effective in its 40,000-subject phase 3 trial.

CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028.

CureVac (CVAC) has reported its fourth quarter 2024 financial results, generating mixed reactions from investors as the company balances promising clinical developments against financial challenges.

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.

CureVac Trading Down 2.5 % Shares of NASDAQ:CVAC opened at $3.12 on Monday. The business has a 50 day moving average of $3.08 and a two-hundred day moving average of $3.17. The company has a ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CVAC: Disclaimer & Disclosure Report an Issue CureVac NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

In this article, we are going to take a look at where CureVac (NASDAQ:CVAC) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness.

Investing.com -- Shares of CureVac (NASDAQ: CVAC) climbed 11% following a favorable patent validity decision in its legal proceedings against BioNTech (NASDAQ: NASDAQ:BNTX). The European Patent Office ...